ASCO 2018 | PROPHECY trial: AR-V7 CTCs as a biomarker in mCRPC

Andrew Armstrong

Andrew Armstrong, MD, from Duke University, Durham, NC, speaks from the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL. Dr Armstrong shares details of the PROPHECY trial (NCT02269982), which is investigating AR-V7 on circulating tumor cells as a prospective predictor in men with metastatic castration-resistant prostate cancer (mCRPC).

Share this video